Evidence map›Paper›PMID 28796845›Full record

ArticlePloS one2017

Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP.

Jongwook Yu, Pyung Chun Oh, Minsu Kim, Jeonggeun Moon, Yae Min Park, Kyounghoon Lee, Soon Yong Suh, Seung Hwan Han, Kyunghee Byun, Taehoon Ahn and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 4 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Observational
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jongwook YuCardiology, Gachon University Gil Medical Center, Incheon, Republic of Korea.
Pyung Chun OhCardiology, Gachon University Gil Medical Center, Incheon, Republic of Korea.
Minsu KimCardiology, Gachon University Gil Medical Center, Incheon, Republic of Korea.
Jeonggeun MoonCardiology, Gachon University Gil Medical Center, Incheon, Republic of Korea.
Yae Min ParkCardiology, Gachon University Gil Medical Center, Incheon, Republic of Korea.
Kyounghoon LeeCardiology, Gachon University Gil Medical Center, Incheon, Republic of Korea.
Soon Yong SuhCardiology, Gachon University Gil Medical Center, Incheon, Republic of Korea.
Seung Hwan HanCardiology, Gachon University Gil Medical Center, Incheon, Republic of Korea.
Kyunghee ByunDepartment of Anatomy and Cell Biology, Graduate School of Medicine, Gachon University, Incheon, Republic of Korea.
Taehoon AhnCardiology, Gachon University Gil Medical Center, Incheon, Republic of Korea.
Woong Chol KangCardiology, Gachon University Gil Medical Center, Incheon, Republic of Korea.ORCID http://orcid.org/0000-0003-4590-7178
Gachon University · KRGachon University Gil Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough soluble suppression of tumorigenicity 2 (sST2) in serum is known to be associated with ischemic heart disease and heart failure, data regarding its prognostic impact in ST-segment elevation myocardial infarction (STEMI) is limited. We evaluated the prognostic impacts of serum sST2 and other serum biomarkers in STEMI patients undergoing primary percutaneous coronary intervention (PCI).

methodsConsecutive all 323 patients with STEMI that underwent primary PCI were enrolled. Blood tests and samples were obtained in an emergency room. The primary endpoint was 1-year major adverse cardiovascular and cerebrovascular events (MACCEs), defined as a composite of cardiovascular death, non-fatal MI, non-fatal stroke, and ischemia-driven revascularization.

resultsMean age was 59.1±13.1 years (men 84%). MACCE (20 cardiovascular deaths, 7 non-fatal MI, 4 non-fatal stroke, 7 ischemia-driven revascularizations) occurred in 38 patients (12%). After adjusting for confounding factors, Cox regression analysis revealed that high serum sST2 (>75.8 ng/mL mean value, adjusted hazard ratio 2.098, 95% CI 1.008-4.367, p = 0.048) and high serum NT-proBNP level (>400 pg/mL, adjusted hazard ratio 2.606, 95% CI 1.086-6.257, p = 0.032) at the time of presentation independently predicted MACCE within a year of primary PCI. Furthermore, when high serum sST2 level was combined with high serum NT-proBNP level, the hazard ratio of MACCE was highest (adjusted hazard ratio 7.93, 95% CI 2.97-20.38, p<0.001).

conclusionElevated serum levels of sST2 or NT-proBNP at the time of presentation were found to predict 1-year MACCE independently and elevated serum levels of sST2 plus NT-proBNP were associated with even poorer prognosis in patients with STEMI undergoing primary PCI.

Indexed as

Percutaneous Coronary InterventionAgedFemaleHumansInterleukin-1 Receptor-Like 1 ProteinMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPrognosisRisk AssessmentRisk FactorsST Elevation Myocardial InfarctionStrokeIL1RL1 protein, humanInterleukin-1 Receptor-Like 1 ProteinNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)

Identifiers

PMID28796845
PMCPMC5552027
OpenAlexW2742986258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.